Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals
This article was originally published in The Pink Sheet Daily
Executive Summary
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.